A large caveat, however, is that the correct dosage or scheduling of IKKβ inhibition is likely to be critical to achieve potentiation, rather than inhibition of the anti-tumour response, due to the importance of NF-κB activity for T cell survival/function [31]. The gene discussed is NFKB1; the disease is neoplasm.